(VIANEWS) – On Friday, shares of AB SCIENCE (AB.PA) dropped 11.92% to EUR3.44, reversing an earlier upward trend and following two consecutive days of losses. Even as CAC 40 index gained 0.28% to EUR7,336.95, performance remains weak with last closing price being EUR3.90 which was 58.15% below 52-week high EUR9.50.
About AB SCIENCE
AB Science S.A. is a pharmaceutical company dedicated to researching, developing, and marketing protein kinase inhibitors. Their lead compound masitinib is currently in Phase III clinical trials for various indications including prostate and pancreatic cancer; amyotrophic lateral sclerosis; multiple sclerosis; Alzheimer’s; severe asthma and mastocytosis diseases as well as Covid-19 treatment trials as well as Phase II trials for treatment purposes; in addition AB Science is developing synthetic microtubule destabilizer for haematological indications (AB8939); since 2001 they operate out of Paris from France with headquarters located there
Yearly Analysis
Based on its current share price of EUR3.44, AB SCIENCE’s stock has experienced significant price fluctuation since reaching its 52-week high of EUR9.50 and low of EUR2.73. This indicates a considerable price movement over the last year.
Investors must remember that a stock’s current price does not necessarily represent its intrinsic value or future performance. Therefore, investors should carefully consider other factors like financial health of the company, industry outlook and overall market conditions before making investment decisions.
Notably, stock price movement over the past year may have been affected by various factors including changes in financial performance, industry trends, or broader economic conditions. Therefore, investors must conduct extensive research before making investment decisions.
Technical Analysis
AB SCIENCE’s stock is currently trading below both its 50-day and 200-day moving averages, signaling a downward trend over both short- and long-term. This could be seen as a bearish signal as it indicates further price erosion for the company.
Additionally, this stock’s volume has increased substantially relative to its average volume indicating increased trading activity and possibly a change in market sentiment. Furthermore, volatility has also been increasing, reaching its highest amplitude ever recorded during last week.
According to the stochastic oscillator, AB SCIENCE’s stock may be considered oversold and therefore an ideal time for investors to buy it; however, prior to making any definitive investment decisions they must first conduct extensive research before taking action.
Quarter Analysis
According to available data, revenue growth for the company has experienced a substantial decrease of 58.3% year-on-year with twelve trailing months revenue totalling 958k indicating an overall slowdown in their revenue growth which may cause investors cause for alarm.
However, before making any investment decisions it’s essential to carefully consider factors like profitability, competitive position and industry outlook of a company. Furthermore, it is imperative to analyze why revenue declined and assess their ability to recover or enhance financial performance.
Although a decline in revenue growth may signal to investors that something is amiss, it’s vitally important that you conduct a comprehensive evaluation of all relevant aspects before making any investment decisions.
Equity Analysis
According to available data, AB SCIENCE currently boasts a trailing twelve months EPS of EUR-0.39. EPS measures the portion of profit allocated per outstanding share in a company’s stock. A negative EPS indicates that rather than making profits over the previous twelve months, losses have occurred instead.
Investors must remember that a negative EPS doesn’t always indicate poor company performance or that its stock is not worthwhile investment. Other considerations, including revenue growth, market share and competitive position of a stock may also play a vital role when assessing it as an investment option. Furthermore, reviewing financial statements provides more complete understanding of their financial health and prospects.
Comparing AB SCIENCE’s earnings per share (EPS) against that of its industry peers or historical levels may also provide additional context when assessing profitability and future growth potential of the company.
More news about AB SCIENCE (AB.PA).
